Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 180
Immunization Safety Review: Vaccines and Autism Appendix B Public Meeting Agenda February 9, 2004 Immunization Safety Review Vaccines and Autism National Academy of Sciences Building Auditorium, 2100 C Street, NW Washington, DC 8:00–8:15 am Welcome and Opening Remarks Marie McCormick, M.D., Sc.D., Committee Chair 8:15–8:30 am Congressional Speakers Congressman Dave Weldon, U.S. House of Representatives 8:30–9:30 am Etiologic Factors and Pathogenesis of Autism: Evidence from Clinical Studies and Animal Models Mady Hornig, M.D., Associate Professor, Columbia University Mailman School of Public Health
OCR for page 181
Immunization Safety Review: Vaccines and Autism 9:30–10:00 am Association of Autistic Spectrum Disorder and MMR Vaccine: A Systematic Review of Current Epidemiological Evidence Kumanan Wilson, M.D., M.Sc., Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Canada 10:00–10:30 am Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects Frank DeStefano, M.D., Centers for Disease Control and Prevention 10:30–10:45 am Break 10:45–11:15 am Exposure to Thimerosal-Containing Vaccines in U.K. Children and Autism Dr. Elizabeth Miller, Head, Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London 11:15–11:45 am Vaccine Safety Datalink Study: Autism Outcome Robert L. Davis, M.D., M.P.H., University of Washington Group Health, Cooperative Departments of Pediatrics Center for Health Studies and Epidemiology 11:45–12:15 pm Study of the Association Between Thimerosal-Containing Vaccine and Autism in Denmark Anders Peter Hviid, M.Sc., Department of Epidemiology Research, State Serum Institute, Copenhagen, Denmark 12:15–12:45 pm Autism and Thimerosal-Containing Vaccines: Analysis of the Vaccine Adverse Events Reporting System (VAERS) Mark R. Geier, M.D., Ph.D., President, The Genetic Centers of America David Geier, President of MedCon 12:45–1:45 pm Lunch
OCR for page 182
Immunization Safety Review: Vaccines and Autism 1:45–2:15 pm A Toxicologist’s View of Thimerosal and Autism H. Vasken Aposhian, Ph.D., Professor, Molecular and Cellular Biology, University of Arizona 2:15–2:45 pm Relation of Neurotoxic Effects of Thimerosal to Autism David Baskin, M.D., Professor of Neurosurgery and Anesthesiology, Baylor College of Medicine 2:45–3:15 pm Thimerosal Exposure from Vaccines and Ethylmercury Accumulation in Nonhuman Primates Dr. Polly Sager, Assistant Director for International Research, National Institute of Allergy and Infectious Diseases 3:15–3:30 pm Break 3:30–4:00 pm Reduced Levels of Mercury in First Baby Haircuts of Autistic Children Boyd Haley, Ph.D., Chairman and Professor, Department of Chemistry, University of Kentucky 4:00–4:30 pm A Case-Control Study of Mercury Burden in Children with Autistic Disorders and Measles Virus Genomic RNA in Cerebrospinal Fluid in Children with Regressive Autism Jeff Bradstreet, M.D., FAAFP, Adjunct Professor, Neurosciences, Stetson University, Director of Clinical Programs, International Child Development Resource Center, Florida 4:30–5:00 pm Autism, Vaccines, and Immune Reactions Vijendra K. Singh, Ph.D., Research Associate Professor, Utah State University 5:00–5:30 pm Public Comment Period 5:30 pm Adjourn
Representative terms from entire chapter: